Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Renee-Marie Ragguett, Samantha J. Yim, Peter T. Ho & Roger S. McIntyre. (2017) Efficacy of levomilnacipran extended release in treating major depressive disorder. Expert Opinion on Pharmacotherapy 18:18, pages 2017-2024.
Read now
Read now
Qunlian Huang, Xiaoyan Zhong, Ye Yun, Bin Yu & Yilan Huang. (2016) Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 12, pages 2707-2714.
Read now
Read now
Gregory M Asnis & Margaret A Henderson. (2015) Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatric Disease and Treatment 11, pages 125-135.
Read now
Read now
Laishun Chen, William M Greenberg, Elimor Brand-Schieber, Julie Wangsa, Antonia Periclou & Parviz Ghahramani. (2015) Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug Design, Development and Therapy 9, pages 3293-3300.
Read now
Read now
Valérie Brunner, Bernadette Maynadier, Laishun Chen, Louise Roques, Isabelle Hude, Sébastien Séguier, Laurence Barthe & Philippe Hermann. (2015) Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Drug Design, Development and Therapy 9, pages 3199-3215.
Read now
Read now
William James Deardorff & George T Grossberg. (2014) A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opinion on Pharmacotherapy 15:17, pages 2525-2542.
Read now
Read now
Articles from other publishers (23)
Teresa Wiesinger, Stefanie Kremer, Tom Bschor & Christopher Baethge. (2023)
Antidepressants and quality of life in patients with major depressive disorder – Systematic review and meta‐analysis of double‐blind, placebo‐controlled
RCTs
. Acta Psychiatrica Scandinavica 147:6, pages 545-560.
Crossref
Crossref
Stefanie Kremer, Teresa Wiesinger, Tom Bschor & Christopher Baethge. (2023) Antidepressants and Social Functioning in Patients with Major Depressive Disorder: Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs. Psychotherapy and Psychosomatics 92:5, pages 304-314.
Crossref
Crossref
Kristin Waters. (2022) The clinical utility of newer antidepressant agents: Understanding the role in management of MDD. Mental Health Clinician 12:5, pages 309-319.
Crossref
Crossref
Erick H. Turner, Andrea Cipriani, Toshi A. Furukawa, Georgia Salanti & Ymkje Anna de Vries. (2022) Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLOS Medicine 19:1, pages e1003886.
Crossref
Crossref
Christian P. Cheung, Mathura T. Thiyagarajah, Haben Y. Abraha, Celina S. Liu, Krista L. Lanctôt, Alex J. Kiss, Mahwesh Saleem, Ari Juda, Anthony J. Levitt, Ayal Schaffer, Amy H. Cheung & Mark Sinyor. (2021) The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. Journal of Affective Disorders 280, pages 140-147.
Crossref
Crossref
Mark Zimmerman, Caroline Balling, Iwona Chelminski & Kristy Dalrymple. (2020) Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications. Journal of Affective Disorders 260, pages 483-488.
Crossref
Crossref
Tina H. Byun, Swarna S. Chaliki & Kenneth G. PooleJrJr. (2019) New Treatment Options for Depression: A Primer for Internists. The American Journal of Medicine 132:6, pages 678-684.
Crossref
Crossref
Suresh Durgam, Changzheng Chen, Raffaele Migliore, Chandran Prakash & Michael E. Thase. (2019) Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. Depression and Anxiety 36:3, pages 225-234.
Crossref
Crossref
Maria Bogdan, Eliza Gofita, Daniela Cornelia Calina, Adina Turcu-Stiolica, Anca Oana Docea, Tudor Adrian Balseanu, Adrian Camen, Gratiela Eliza Popa, Gabriela Rusu, Ina Cristofor, Liliana Pavel & Liliana Mititelu-Tartau. 2018. Pharmacokinetics and Adverse Effects of Drugs - Mechanisms and Risks Factors. Pharmacokinetics and Adverse Effects of Drugs - Mechanisms and Risks Factors.
Hairong He, Wei Wang, Jun Lyu, Jie Zheng, Liyang Guo, Xiaofang An, Yajuan Fan & Xiancang Ma. (2018) Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 96, pages 247-259.
Crossref
Crossref
Michael E. Thase, Carl Gommoll, Changzheng Chen, Kenneth Kramer, Arif Khan & Suresh Durgam. (2017) Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. CNS Spectrums 22:6, pages 475-483.
Crossref
Crossref
Kai G. Kahl, Mechthild Westhoff-Bleck & Tillmann H.C. Krüger. (2017) Effects of psychopharmacological treatment with antidepressants on the vascular system. Vascular Pharmacology 96-98, pages 11-18.
Crossref
Crossref
David V. Sheehan, Kazuyuki Nakagome, Yuko Asami, Elizabeth A. Pappadopulos & Matthieu Boucher. (2017) Restoring function in major depressive disorder: A systematic review. Journal of Affective Disorders 215, pages 299-313.
Crossref
Crossref
Pierre Blier, Carl Gommoll, Changzheng Chen & Kenneth Kramer. (2017) Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials. Journal of Affective Disorders 210, pages 273-279.
Crossref
Crossref
Roger S. McIntyre, Carl Gommoll, Changzheng Chen & Adam Ruth. (2016) The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS Spectrums 21:5, pages 385-392.
Crossref
Crossref
Susan G. Kornstein, Carl Gommoll, Changzheng Chen & Kenneth Kramer. (2016) The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD. Journal of Affective Disorders 193, pages 137-143.
Crossref
Crossref
Mark Zimmerman, Matthew Multach, Emily Walsh, Lia K. Rosenstein, Douglas Gazarian & Heather L. Clark. (2016) Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. CNS Drugs 30:3, pages 185-191.
Crossref
Crossref
Mark Zimmerman, Heather L. Clark, Matthew D. Multach, Emily Walsh, Lia K. Rosenstein & Douglas Gazarian. (2016) Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. Journal of Affective Disorders 190, pages 357-361.
Crossref
Crossref
William James Deardorff & George T. Grossberg. (2015) The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Current Geriatrics Reports 4:4, pages 301-311.
Crossref
Crossref
Laishun Chen, Ramesh Boinpally, Nayra Gad, William M. Greenberg, Julie Wangsa, Antonia Periclou & Parviz Ghahramani. (2015) Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. Clinical Drug Investigation 35:10, pages 601-612.
Crossref
Crossref
Laishun Chen, William M. Greenberg, Carl Gommoll, Joann O’Connor, Stephen R. Zukin, Antonia Periclou & Parviz Ghahramani. (2015) Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. Clinical Therapeutics 37:9, pages 2059-2070.
Crossref
Crossref
Stuart A. Montgomery, Carl P. Gommoll, Changzheng Chen & William M. Greenberg. (2014) Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectrums 20:2, pages 148-156.
Crossref
Crossref
Lesley J. Scott. (2014) Levomilnacipran Extended-Release: A Review of Its Use in Adult Patients with Major Depressive Disorder. CNS Drugs 28:11, pages 1071-1082.
Crossref
Crossref